一心堂药业集团股份有限公司 电话业绩说明会记录 时间：2022 年 8 月 30 日 9:00-10:00 地点：一心堂药业集团股份有限公司总部 召开方式：公司 2022 年半年度报告业绩电话交流会 投资者：东北证券 刘宇腾 文将儒、中信证券 沈睦钧等投资者共 115 人。 接待人：副总裁兼董事会秘书 李正红、证券总监 肖冬磊 一、公司基本情况： 1、主要财务指标：2022 年 1-6 月，公司实现营业收入 79.65 亿元，同比增 长 18.85%。归母净利润 4.18 亿，同比下降 20.16%。收入增速快于利润增速，主 要是由于 2021 年第三季度并表本草堂公司，本草堂主要业务是分销及加盟，利 润率较低。公司 2022 年第一季度及第二季度，营业收入分别为 39.95 亿、39.7 亿，归母净利润分别为 1.79 亿、2.39 亿，第二季度较第一季度有所恢复，环比 增长 33.16%。 2、门店数量变化：截至 2022 年 6 月 30 日，公司共拥有直营连锁门店数量 8990 家，2022 年上半年新开门店 578 家，关闭门店 61 家，搬迁门店 87 家，净 增加 430 家。其中第一季度净增加 ...

投资者关系活动记录表 证券代码：002727 证券简称：一心堂 一心堂药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-------------------------------------------------|--------------------| | | | 编号：TG202208-001 | | 投资者关系活动类 | 特定对象调研 □分析师会议 | | | 别 | □媒体采访 ■业绩说明会 | | | | □新闻发布会 | 路演活动 | | | □现场参观 | | | | ■其他 （电话会议） | | | 参与单位名称及人 员姓名 | 东北证券 刘宇腾 文将儒、中信证券 115 人。 | 沈睦钧等投资者共 | | 时间 2022 | 年 8 月 30 日 | 9:00-10:00 | | | 地点 一心堂药业集团股份有限公司总部 | | | 公司接待人员姓名 | 副总裁兼董事会秘书 李正红； 证券总监 肖冬磊。 | | | 投资者关系活动主 要内容介绍 | 公司 2022 | 年半年度业绩交流会 | ...

一心堂药业集团股份有限公司 电话业绩说明会记录 时间：2022 年 10 月 28 日 10:00-11:00 地点：一心堂药业集团股份有限公司总部 召开方式：公司 2022 年第三季度报告业绩电话交流会 投资者：中信建投 贺菊颖 刘若飞 谢俊等投资者共 89 人。 接待人：副总裁兼董事会秘书 李正红、证券总监 肖冬磊 一、公司基本情况： 1、主要财务指标：2022 年 1-9 月，公司实现营业收入 120.25 亿元，同比 增长 14.55%。归母净利润 6.77 亿，同比下降 11.33%。公司 2022 年第一季度、 第二季度及第三季度，营业收入分别为 39.95 亿、39.7 亿、40.60 亿，归母净利 润分别为 1.79 亿、2.39 亿、2.60 亿，同比分别-31.17%、-9.26%、7.95%。归母 净利润同比逐季度改善。 2022 年 3 季度公司布局的多个省份陆续公布出新冠肺炎阳性病例，导致公 司短暂停业的门店超过 600 家。因疫情防控需要被暂时性隔离的员工有 1600 多人，涉及到一退两抗药品下架管控的门店有 1800 多家，占门店总数的 20%。 至三季度报告披露日，各地因疫情得 ...

投资者关系活动记录表 证券代码：002727 证券简称：一心堂 一心堂药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------------------------|---------------------------------------------------| | | | 编号：TG202210-001 | | 投资者关系活动类 | | 特定对象调研 □分析师会议 | | 别 | □媒体采访 ■业绩说明会 | | | | □新闻发布会 | 路演活动 | | | □现场参观 | | | | ■其他 （电话会议） | | | 参与单位名称及人 员姓名 | | 中信建投 贺菊颖 刘若飞 谢俊等投资者共 89 人。 | | 时间 2022 | 年 10 月 28 日 | 10:00-11:00 | | 地点 | 一心堂药业集团股份有限公司总部 | | | | 公司接待人员姓名 副总裁兼董事会秘书 证券总监 肖冬磊。 | 李正红； | | 投资 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥4,060,397,555.21, representing a year-on-year increase of 6.94%[5]. - The net profit attributable to shareholders for Q3 2022 was ¥259,120,858.08, showing a year-on-year increase of 7.95%[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥249,813,759.63, up by 5.90% year-on-year[5]. - The net profit for the first three quarters of 2022 totaled ¥677,365,857.29, which is a decrease of 11.33% compared to the same period last year[11]. - The net profit for the current period is ¥674,791,755.39, a decrease of 11.5% compared to ¥762,213,079.85 in the previous period[46]. - The total profit for the current period is ¥771,171,343.13, down 11.4% from ¥870,155,127.54 in the previous period[46]. - The company's net profit attributable to shareholders for the period increased to CNY 4,002,754,453.32, compared to CNY 3,504,242,753.53 at the beginning of the year, showing a growth of approximately 14.2%[42]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,477,301,792.16, reflecting a significant increase of 94.43% compared to the same period last year[5]. - Operating cash flow net amount increased by 94.43% to ¥1,477,301,792.16 due to higher sales collections[23]. - Cash outflow from operating activities totaled ¥10,007,294,050.71, an increase from ¥9,423,775,005.16 in the previous period, reflecting a growth of approximately 6.2%[54]. - Net cash flow from operating activities was ¥1,477,301,792.16, significantly up from ¥759,819,437.97, indicating an increase of about 94.3%[54]. - Cash inflow from investment activities was ¥1,207,552,247.37, down from ¥2,634,818,963.04, representing a decrease of approximately 54.3%[54]. - Net cash flow from investment activities was ¥19,866,326.11, a decline from ¥673,651,861.65, showing a decrease of about 97.0%[54]. - Cash inflow from financing activities totaled ¥250,008,756.05, compared to ¥18,672,240.00 in the previous period, marking a substantial increase[54]. - Net cash flow from financing activities was -¥862,337,565.29, an improvement from -¥935,430,305.48, indicating a reduction in cash outflow[54]. - The net increase in cash and cash equivalents was ¥635,284,039.19, up from ¥498,024,543.92, reflecting an increase of approximately 27.7%[54]. - The ending balance of cash and cash equivalents reached ¥2,297,227,613.70, compared to ¥1,541,494,011.21 in the previous period, showing a growth of about 49.0%[54]. Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥15,071,087,038.65, which is a 5.12% increase from the end of the previous year[5]. - The company's total assets as of September 30, 2022, amounted to CNY 15,071,087,038.65, compared to CNY 14,337,349,279.85 at the beginning of the year, reflecting a growth of approximately 5.1%[42]. - Current assets totaled CNY 8,488,311,849.83 as of September 30, 2022, an increase from CNY 7,692,379,928.77 at the start of the year, marking a rise of about 10.3%[42]. - The total liabilities as of September 30, 2022, were CNY 7,872,440,709.04, up from CNY 7,664,801,674.77 at the beginning of the year, indicating an increase of about 2.7%[42]. - The company's long-term equity investments increased to CNY 164,735,130.93 from CNY 107,218,078.84, indicating a growth of about 53.5%[42]. - The total owner's equity as of September 30, 2022, was CNY 7,198,646,329.61, compared to CNY 6,672,547,605.08 at the beginning of the year, reflecting an increase of approximately 7.9%[42]. Store Operations - As of September 30, 2022, the company had a total of 9,164 retail stores, with a net increase of 604 stores during the reporting period[34]. - The company temporarily closed over 600 stores due to the pandemic, affecting more than 20% of its total stores[30]. - The company opened 885 new stores during the reporting period while closing 137 stores[34]. - The company has expanded its store network in provinces outside Yunnan, with over 1,200 stores in Sichuan and over 800 in Guangxi[34]. - The company has a balanced development of stores across various administrative regions, maintaining a high-density network layout[32]. Earnings and Expenses - The basic earnings per share for Q3 2022 was ¥0.4364, an increase of 7.30% year-on-year[5]. - The diluted earnings per share for Q3 2022 was ¥0.4357, reflecting a year-on-year increase of 7.45%[5]. - The weighted average return on equity for Q3 2022 was 3.71%, a slight decrease of 0.02% compared to the previous year[5]. - Sales expenses increased to ¥3,016,640,548.79, up 9.6% from ¥2,754,665,283.82 in the previous period[46]. - Research and development expenses remained stable at ¥3,851,636.92, slightly down from ¥3,866,498.12[46]. - The company recorded a financial expense of ¥71,251,251.41, up from ¥56,993,715.76 in the previous period[46]. - The investment income for the current period is ¥5,129,427.62, a significant decrease from ¥14,553,750.74 in the previous period[46]. - The company experienced a credit impairment loss of -¥9,304,160.31, compared to -¥4,025,093.11 in the previous period[46]. Other Financial Metrics - Other income decreased by 54.07% to ¥17,780,667.87 as tax incentives reduced[18]. - Cash received from tax refunds increased by 6976.68% to ¥1,600,849.39 due to VAT refunds[23]. - Trading financial assets decreased by 95.26% to ¥14,079,493.84 due to the recovery of matured financial products[16]. - Accounts receivable financing increased by 54.74% to ¥40,136,401.52 driven by an increase in receivable notes[16]. - Other receivables rose by 45.63% to ¥300,923,059.89 primarily due to increased deposits and other receivables[16]. - Short-term borrowings surged by 185.94% to ¥365,138,650.00 as a result of increased bank loans from subsidiaries[16]. - Inventory as of September 30, 2022, was CNY 3,383,811,024.58, slightly up from CNY 3,316,964,090.61 at the start of the year, reflecting an increase of approximately 2.0%[38]. - The company reported accounts receivable of approximately CNY 1.73 billion as of September 30, 2022, up from CNY 1.35 billion at the beginning of the year[35]. - The company reported a decrease in other comprehensive income, with a net amount of -¥1,954,497.81 compared to ¥135,431.84 in the previous period[50]. - The basic earnings per share for the current period is 1.1424, down from 1.2943 in the previous period[50].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[23]. - Net profit attributable to shareholders reached RMB 150 million, up 10% compared to the same period last year[23]. - The company's operating revenue for the reporting period was ¥7,965,021,522.51, an increase of 18.85% compared to ¥6,701,565,933.39 in the same period last year[30]. - The net profit attributable to shareholders was ¥418,244,999.21, a decrease of 20.16% from ¥523,869,384.37 year-on-year[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥397,833,190.34, down 22.32% from ¥512,163,946.32 in the previous year[30]. - The net cash flow from operating activities increased by 33.15% to ¥625,774,512.58 from ¥469,976,769.61 in the same period last year[30]. - Retail revenue accounted for 79.32% of total revenue, amounting to ¥6,317,704,462.41, with a year-on-year growth of 5.11%[87]. - Franchise revenue surged by 824.30% to ¥23,689,329.76, up from ¥2,562,950.19 in the previous year[87]. Market Expansion and Strategy - The number of retail outlets increased to 1,200, marking a growth of 8% from the previous year[23]. - The company has expanded its market presence in southern China, with a focus on increasing its distribution network[23]. - A strategic acquisition of a local pharmaceutical company is in progress, aimed at enhancing product offerings and market share[23]. - The company is focusing on expanding its retail chain in the Southwest and South China regions while also considering the North China market[41]. - The company is actively exploring new business models in health management, including smart pharmacies and the application of new technologies like AI robots and facial recognition in retail stores[43]. - The company aims to enhance store operational quality and optimize single-store performance through targeted adjustment plans, focusing on new store promotions and potential consumer engagement[48]. - The company is committed to building an integrated online and offline marketing network to enhance its overall operational efficiency[53]. - The company is actively expanding its store network through a combination of new openings and acquisitions, aiming to enhance its competitive strength in the market[126]. Investment and Development - The company plans to invest RMB 200 million in new product development and technology upgrades in the next fiscal year[23]. - The company has initiated a multi-faceted innovation strategy, expanding into lottery and personal care products to attract a broader consumer base and increase store visit frequency[48]. - The company is committed to integrating traditional Chinese medicine into its business strategy, responding to national health initiatives and market demand[52]. - The company has developed a complete industrial chain for traditional Chinese medicine, including seedling cultivation, processing, and retail, leveraging Yunnan's rich herbal resources[79]. - The company plans to invest a total of RMB 152 million in various projects, with a current investment of RMB 147.34 million, achieving 97% of the planned investment[114]. Customer Engagement and Sales Channels - The company is prioritizing the development of online-to-offline (O2O) sales channels to boost customer engagement[23]. - The company's e-commerce sales reached 262 million yuan in the first half of 2022, a year-on-year increase of 62.64%, with O2O sales growing by 77.59%[66]. - O2O business accounted for 85.53% of total e-commerce sales, with self-operated O2O average transaction value being 4.17 times that of third-party O2O[66]. - The average transaction value for members is 2.73 times that of non-members, indicating strong member loyalty and spending[63]. Human Resources and Management - The company has trained 73 mid-to-senior management personnel through a specialized program to enhance leadership capabilities and align with long-term strategic goals[48]. - The company emphasizes the importance of human resources in driving operational efficiency and competitive advantage, investing in talent development for store managers[51]. - The company has a comprehensive training system in place to develop core competencies among employees, ensuring a skilled workforce to support its growth[82]. Risk Management and Compliance - The management highlighted potential risks including macroeconomic fluctuations and regulatory changes impacting the pharmaceutical industry[5]. - The company is closely monitoring changes in industry regulations and policies, adapting its business model to mitigate risks associated with stricter regulatory environments[123]. - The company faces risks related to the inability to renew leases for most of its stores, which could impact operations due to potential rent increases or property redevelopment[123]. - The company has implemented strict management controls in drug quality and sales industry standards to ensure compliance and professionalism[186]. Corporate Governance and Social Responsibility - The company emphasizes the protection of shareholder and creditor rights as a key obligation, ensuring compliance with relevant laws and regulations[140]. - The company actively participates in social responsibility initiatives, including providing educational resources to impoverished areas and donating pandemic prevention materials[144]. - The company maintains a commitment to employee rights and development, providing a supportive environment for employee growth and satisfaction[141]. - The company adheres to energy-saving and emission-reduction policies, enhancing economic, social, and environmental benefits[144]. Stock and Financial Management - The company has established a stock incentive plan, granting 5.122 million restricted shares at a price of 10.42 CNY per share, representing 0.90% of the total issued share capital[133]. - The company has not distributed cash dividends or bonus shares for the half-year period, nor has it converted capital reserves into share capital[132]. - The company reported a commitment to repurchase all newly issued shares if any false statements or omissions are identified in the prospectus, with a repurchase price based on the higher of the paid-in capital plus interest or the average price over the last 30 trading days[148]. - The company has maintained a good usage status of the raised funds, ensuring no impact on the planned usage[110].

Financial Performance - Revenue for Q1 2022 reached ¥3,995,396,903.45, an increase of 16.53% compared to ¥3,428,551,312.20 in the same period last year[3] - Net profit attributable to shareholders was ¥179,380,370.34, a decrease of 31.17% from ¥260,630,426.63 year-on-year[3] - Cash flow from operating activities was ¥131,844,493.03, down 48.48% from ¥255,912,355.04 in the previous year[3] - The total operating costs for Q1 2022 were ¥3,795,097,759.61, up from ¥3,137,775,038.88 in the previous year, indicating a rise of about 20.9%[31] - The net profit for the current period is CNY 175,075,166.71, a decrease of 32.6% compared to CNY 259,964,241.59 in the previous period[34] - The total profit for the current period is CNY 209,312,960.76, down 28.2% from CNY 291,404,921.67 in the previous period[34] - Basic earnings per share for the current period is CNY 0.3039, down from CNY 0.4416 in the previous period[42] Cash Flow and Investments - Cash flow from investment activities turned negative at -$412.48 million, a decrease of 227.65% year-on-year[1] - The total cash outflow from investment activities was $697.77 million, down from $1.12 billion in the previous period, indicating a decrease of approximately 37.5%[50] - The net cash flow generated from investment activities was -$412.48 million, compared to a positive cash flow of $323.14 million in the prior period[50] - Cash inflow from financing activities amounted to $50 million, an increase from $17.97 million in the previous period[50] - The net cash flow from financing activities was -$263.04 million, an improvement from -$329.29 million in the previous period[50] - The beginning balance of cash and cash equivalents was $1.66 billion, up from $1.04 billion in the previous period[50] - The ending balance of cash and cash equivalents was $1.12 billion, down from $1.29 billion in the previous period[50] Assets and Liabilities - Total assets at the end of the reporting period were ¥14,498,046,678.44, reflecting a 1.12% increase from ¥14,337,349,279.85 at the end of the previous year[3] - As of the end of Q1 2022, the company's current assets totaled ¥7,839,216,055.93, compared to ¥7,692,379,928.77 at the beginning of the year, reflecting a slight increase[23] - The company's inventory stood at ¥3,268,667,415.88 at the end of Q1 2022, down from ¥3,316,964,090.61 at the start of the year[23] - The total liabilities decreased slightly from ¥7,664,801,674.77 at the beginning of the year to ¥7,652,790,762.86 by the end of Q1 2022[29] - The company's equity attributable to shareholders increased from ¥6,577,747,355.32 at the beginning of the year to ¥6,754,760,869.45 by the end of Q1 2022[29] Operational Challenges - The company faced operational challenges due to COVID-19, with nearly 500 stores temporarily closed and 2,146 stores required to remove certain products from sale due to pandemic control measures[19] - The company reported a cash flow impact from the pandemic, particularly affecting the reconciliation and collection of commercial insurance payments in Shanghai[19] - The company plans to gradually resume sales of previously removed products as pandemic control measures improve across various regions[19] - The company continues to enhance its retail chain network and operational capabilities to mitigate risks associated with the ongoing pandemic[19] Shareholder Information - The total number of common shareholders at the end of the reporting period was 40,361, with the largest shareholder holding 30.55%[2] - The largest shareholder, Ruan Hongxian, holds 30.55% of shares, with 44.94 million shares pledged[2] Store Expansion and Strategy - The company opened 298 new stores and closed 11, resulting in a net increase of 249 stores, bringing the total to 8,809[18] - The proportion of direct stores in townships reached 18.87%, indicating a focus on rural market expansion[18] - The company has a strategic plan for store expansion, aligning with its growth objectives[18] Research and Development - Research and development expenses decreased by 49.88% to ¥962,076.91, indicating reduced spending on R&D projects[8] - Research and development expenses decreased to CNY 962,076.91, down 50.0% from CNY 1,919,386.92 in the previous period[34] Other Income and Expenses - Other income rose by 126.08% to ¥16,316,787.80, primarily from increased VAT exemptions[8] - Sales expenses increased to CNY 1,002,415,085.74, up 18.9% from CNY 843,388,423.48 in the previous period[34] - The company experienced a 531.12% increase in credit impairment losses, amounting to -¥10,008,160.36, due to an increase in receivables[8] - The company recorded a loss in investment income of CNY 734,086.72 compared to a gain of CNY 9,222,832.44 in the previous period[34] Audit Status - The company’s first quarter report was not audited, indicating a potential area for investor scrutiny[51]

Financial Performance - The company's operating revenue for 2021 was ¥14,587,401,324.01, representing a 15.26% increase from ¥12,656,284,259.54 in 2020[30]. - The net profit attributable to shareholders for 2021 was ¥921,583,567.71, up 16.66% from ¥789,960,226.95 in 2020[30]. - The net cash flow from operating activities increased by 73.38% to ¥1,791,674,042.72 in 2021, compared to ¥1,033,358,977.02 in 2020[30]. - The basic earnings per share for 2021 was ¥1.5615, a 13.13% increase from ¥1.3803 in 2020[30]. - Total assets at the end of 2021 reached ¥14,337,349,279.85, a 53.70% increase from ¥9,328,305,421.12 at the end of 2020[30]. - The net assets attributable to shareholders increased by 14.09% to ¥6,577,747,355.32 at the end of 2021, compared to ¥5,765,406,145.25 at the end of 2020[30]. - The company's diluted earnings per share for 2021 was ¥1.5560, reflecting a 12.91% increase from ¥1.3781 in 2020[30]. - The company reported a quarterly revenue of ¥4,089,099,944.69 in Q4 2021, showing a strong performance in the last quarter[35]. Shareholder Information - The company reported a cash dividend of 3.00 RMB per 10 shares (including tax) for the 2021 fiscal year[5]. - As of December 31, 2021, the largest shareholder, Mr. Ruan Hongxian, held 181,921,090 shares, accounting for 30.51% of the total shares[26]. - The company has not announced any significant changes in its controlling shareholders since its establishment[26]. - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[171]. Business Operations - The company has not changed its main business since its listing[26]. - The company operates under the stock code 002727 on the Shenzhen Stock Exchange[21]. - The company emphasizes the importance of risk factors affecting its operations, including macroeconomic and market risks[5]. - The company has a commitment to ensuring the accuracy and completeness of its financial reports, as stated by its management[5]. - The company has engaged Dongxing Securities as a sponsor for its public issuance of convertible bonds, with ongoing supervision until the end of 2020[27]. - The company operates a retail chain model, focusing on direct sales from company-owned stores, which enhances brand consistency and service quality[47]. - The company has over 1,600 stores across provincial, municipal, county, and township markets, establishing a unique integrated development pattern[51]. - The company has established a self-owned logistics network covering 6 provinces, 2 municipalities, and 1 autonomous region, enhancing service capabilities[56]. Market Position and Strategy - The retail pharmaceutical market in China reached a scale of 511.9 billion, with a year-on-year growth of 10.1%, indicating a stable growth trend in the industry[45]. - The company ranked fourth in the 2020-2021 comprehensive competitiveness index of retail pharmaceutical enterprises, highlighting its strong market position[45]. - The company is positioned to benefit from long-term growth opportunities in the pharmaceutical retail sector due to increasing healthcare demands and an aging population[46]. - The company is exploring a diversified "big health pharmacy" business model, including health foods and personal care products[50]. - The company has implemented a multi-channel sales network, integrating online and offline operations through its O2O business model[55]. - The company is actively responding to healthcare policy changes, positioning itself to benefit from the shift of prescription drugs from hospitals to retail[50]. Customer Engagement and Sales - The company has focused on customer relationship management through a CRM system to enhance customer satisfaction and loyalty[70]. - As of December 31, 2021, the company had 30 million active members, a year-over-year increase of 25% from the end of 2020, and a quarter-over-quarter increase of 2 million members[71]. - The average transaction value for members in 2021 was 95.37 yuan, with a member repurchase rate of 35.95%, an increase of 3.23 percentage points compared to 2020[71]. - The company's e-commerce business generated total sales of 380 million yuan in 2021, with O2O sales accounting for 80.28% of total e-commerce sales, showing a significant increase from the previous year[71]. - The company achieved a sales ratio of 43.80% from medical insurance card sales, an increase of 1.99 percentage points compared to 2020[68]. Investment and Financial Management - The company has established a dedicated bank account for the management of raised funds, ensuring compliance with regulations and proper usage[123]. - The company has returned all idle raised funds of RMB 400 million to the fundraising account as of March 9, 2021, ensuring no impact on the normal use of raised funds[131]. - The company plans to temporarily use up to RMB 350 million of idle raised funds to supplement working capital, with a usage period of 12 months from the date of shareholder approval[131]. - The total investment amount for the reporting period reached ¥409,789,990, a significant increase of 419.84% compared to ¥78,830,010 in the same period last year[110]. - The company has completed investments in various sectors, including retail pharmacy and medical consulting services[113]. Governance and Compliance - The company emphasizes timely and accurate information disclosure, adhering to legal and regulatory requirements to maintain investor trust[159]. - The company is actively monitoring national policy trends and adjusting its business model to mitigate risks associated with regulatory changes[149]. - The company is committed to complying with regulatory requirements to ensure the legal and effective use of raised funds[131]. - The company has established a comprehensive set of quality control measures to mitigate drug safety risks, ensuring strict adherence to regulatory standards[146]. Future Outlook - The company plans to enhance its market presence in the southwestern region while also focusing on the southern and northern regions of China[61]. - The company aims to improve customer satisfaction through diversified chronic disease management services and health care stations[60]. - The company plans to expand its store network through a combination of new openings and acquisitions to enhance its competitive strength in a rapidly intensifying market[149]. - The company is focusing on developing personal care and beauty flagship stores to attract younger customer demographics, moving beyond its traditional older customer base[74].

Financial Performance - The company's revenue for Q3 2021 reached ¥3,796,735,445.93, an increase of 18.29% compared to the same period last year[3] - Net profit attributable to shareholders was ¥240,034,304.78, reflecting a growth of 27.83% year-on-year[3] - The net profit excluding non-recurring gains and losses was ¥235,900,947.79, up by 31.07% compared to the previous year[3] - The basic earnings per share (EPS) was ¥0.4067, representing a 22.94% increase year-on-year[3] - Total operating revenue for the third quarter of 2021 reached ¥10,498,301,379.32, an increase of 13.7% compared to ¥9,238,762,435.38 in the same period of 2020[32] - Net profit for the third quarter was ¥762,213,079.85, representing a 26.2% increase from ¥603,994,637.57 in the previous year[35] - The company reported a profit before tax of ¥870,155,127.54, compared to ¥767,510,240.34 in the previous year, an increase of 13.4%[35] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥13,447,513,540.76, a 44.16% increase from the end of the previous year[3] - The company's total liabilities increased to ¥6,940,241,350.55 from ¥3,547,811,380.18, marking an increase of 95.5% year-over-year[28] - The total equity attributable to shareholders of the parent company rose to ¥6,406,303,508.53, up from ¥5,765,406,145.25, indicating an increase of 11.1%[28] - Total assets reached ¥13,447,513,540.76 as of September 30, 2021, compared to ¥9,328,305,421.12 at the end of 2020, showing an increase of approximately 44.5%[25] - Total liabilities increased from 3.55 billion to 5.49 billion, reflecting a growth of about 54.7%[50] - Current liabilities increased from 3.53 billion to 4.23 billion, an increase of approximately 19.6%[50] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥759,819,437.97, showing a growth of 12.90%[3] - The company reported a 394.30% increase in net cash flow from investing activities to CNY 673,651,861.65, due to the recovery of maturing financial products[10] - Operating cash inflow from sales reached ¥10,035,983,929.82, up from ¥9,090,618,492.56, indicating an increase of about 10.4%[38] - Net cash flow from operating activities was ¥759,819,437.97, compared to ¥673,004,795.75 in the previous period, reflecting a growth of approximately 12.9%[38] - Total cash and cash equivalents at the end of the period stood at ¥1,541,494,011.21, an increase from ¥1,431,295,226.83, representing a growth of about 7.7%[41] Investments and Expenses - Research and development expenses surged by 343.49% to CNY 3,866,498.12, reflecting increased investment in traditional Chinese medicine projects[9] - Financial expenses skyrocketed by 1422.04% to CNY 56,993,715.76, mainly due to increased leasing interest expenses following the new leasing standards[9] - Research and development expenses for the quarter were ¥3,866,498.12, significantly higher than ¥871,840.16 in the same period last year, reflecting a focus on innovation[32] - The company’s cash flow from investment activities was significantly impacted, with cash paid for investments totaling ¥1,472,800,741.00, down from ¥3,731,200,000.00, a decrease of about 60.5%[41] Market Expansion and Strategy - The company did not report any significant new product developments or market expansion strategies during this quarter[8] - The company continues to expand its market presence, focusing on the Sichuan-Chongqing region and enhancing its network layout[18] - The company aims to enhance its brand influence and sales capabilities through a structured approach to market expansion[21] - The company is actively exploring digital development paths and innovative business models to meet diverse consumer health service needs[18] Store Operations - As of September 30, 2021, the total number of direct chain stores reached 8,356, with a net increase of 1,151 stores during the reporting period[18] - The company opened 1,300 new stores while closing 26 and relocating 123 stores in the same period[21] Other Financial Metrics - The weighted average return on equity (ROE) was 3.73%, a slight increase of 0.02% compared to the previous year[3] - Minority interests surged by 569.20% to CNY 100,968,681.68, resulting from the acquisition of Bencao Tang[9] - Deferred tax assets remained unchanged at 27.62 million, indicating stability in this area[50] - The company reported a total of 2.61 billion in non-current assets as of December 31, 2020, which increased to 4.88 billion by January 1, 2021[50] Audit and Reporting - The third quarter report for 2021 was not audited, which may affect the reliability of the financial data presented[51]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 15%[22]. - Net profit attributable to shareholders reached RMB 150 million, up 10% compared to the same period last year[22]. - The company's operating revenue for the reporting period was ¥6,701,565,933.39, an increase of 11.16% compared to ¥6,028,944,410.23 in the same period last year[29]. - The net profit attributable to shareholders was ¥523,869,384.37, reflecting a growth of 25.82% from ¥416,355,524.37 year-on-year[29]. - The basic earnings per share increased to ¥0.8876, representing a 21.04% rise from ¥0.7333 in the same period last year[29]. - Future guidance indicates expected revenue growth of 20% for the second half of 2021[22]. - The gross margin improved to 35%, an increase of 5 percentage points from the previous year[22]. - The company reported a significant increase in investment, with total investments of ¥214,779,990.00, up 410.17% from ¥42,100,010.00 in the previous year[84]. Market Expansion and Strategy - The number of retail pharmacies increased to 1,200, with a growth rate of 20% year-on-year[22]. - The company plans to expand its market presence in southern China, targeting a 25% increase in market share by the end of 2022[22]. - The company is exploring a diversified "big health pharmacy" model, focusing on health foods and personal care products[45]. - The company’s strategic focus includes expanding its presence in rural markets, where demand for healthcare is expected to rise significantly[46]. - The company is actively expanding its store network through both new openings and acquisitions to enhance its competitive position[98]. Research and Development - The company has invested RMB 50 million in R&D for new drug development, aiming to introduce two new products by the end of 2021[22]. - The company's R&D investment increased significantly by 661.32%, amounting to approximately ¥3.80 million, reflecting a focus on new product development[70]. Customer Engagement and Services - The company has established a customer relationship management system to provide in-depth services such as chronic disease management[46]. - The membership base has grown to 26 million, with an increase of 2 million members in the first half of 2021[56]. - The company aims to enhance customer satisfaction through diversified chronic disease management services, integrating health management and medication guidance[70]. Operational Efficiency - The average daily revenue per square meter across all stores is 42.46 RMB, with the highest efficiency in township-level stores at 43.18 RMB[50]. - The average rent efficiency across all stores is 15.86, with the highest efficiency in township-level stores at 26.08[50]. - The company has developed its own logistics network covering 6 provinces, 2 municipalities, and 1 autonomous region, enabling a unified inventory system for nationwide supply[63]. Corporate Governance and Compliance - The company emphasizes the protection of shareholder rights and has established a comprehensive internal control system to safeguard the interests of all shareholders and creditors[111]. - The company is committed to adhering to regulatory standards and has implemented internal controls to monitor compliance with its commitments[126]. - The company has a long-term commitment to ensure the accuracy and completeness of its financial disclosures, with penalties for non-compliance including salary deductions[126]. Social Responsibility - The company actively participates in social welfare activities, including poverty alleviation and community support initiatives, contributing to local economic development[111]. - The company has created numerous job opportunities through social and campus recruitment, helping to alleviate employment pressure in society[111]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 30,499[179]. - The largest shareholder, Ruan Hongxian, holds 30.51% of the shares, totaling 181,921,090 shares[185]. - The total number of shares held by the top five shareholders accounts for 55.08% of the total shares[185].